Concepedia

Effect of Fluticasone With and Without Salmeterol on Pulmonary Outcomes in Chronic Obstructive Pulmonary Disease

Thérèse Lapperre

Annals of Internal Medicine · 2009 · 185 citations · 34 references

DOIFull text

Open access

Abstract

ICS therapy decreases inflammation and can attenuate decline in lung function in steroid-naive patients with moderate to severe COPD. Adding LABAs does not enhance these effects. .

References

34

The Nature of Small-Airway Obstruction in Chronic Obstructive Pulmonary Disease

James C. Hogg, Fanny Chu, Soraya Utokaparch et al. · New England Journal of Medicine · 2004 · 3.7K citations · Full text

Salmeterol and Fluticasone Propionate and Survival in Chronic Obstructive Pulmonary Disease

Peter Calverley, Julie A. Anderson, Bartolomé R. Celli et al. · New England Journal of Medicine · 2007 · 3.2K citations · Full text

A Self-complete Measure of Health Status for Chronic Airflow Limitation: The St. George's Respiratory Questionnaire

Paul Jones, Frances Quirk, Chloë M. Baveystock et al. · American Review of Respiratory Disease · 1992 · 3K citations

Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial

PS Burge · BMJ · 2000 · 1.7K citations · Full text

Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial

Peter M.A. Calverley, Romain Pauwels, Jørgen Vestbo et al. · The Lancet · 2003 · 1.2K citations

, , +3